Catalym Gmbh
Clinical trials sponsored by Catalym Gmbh, explained in plain language.
-
New drug combo aims to shrink bladder tumors before surgery
Disease control OngoingThis study tests whether adding the experimental drug visugromab to standard immunotherapy can help shrink muscle-invasive bladder cancer before surgery. About 31 adults who cannot or choose not to receive cisplatin chemotherapy will receive the combination before having their bl…
Phase: PHASE2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated May 17, 2026 11:37 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called visugromab (CTL-002) in people with advanced solid tumors that have stopped responding to standard treatments. The drug is given alone or together with an approved immunotherapy. The goal is to see if it is safe and can help shrink tumors. About…
Phase: PHASE1, PHASE2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated May 13, 2026 16:03 UTC